| 1.5 0.11 (7.91%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.78 | 1-year : | 2.08 |
| Resists | First : | 1.52 | Second : | 1.78 |
| Pivot price | 1.4 |
|||
| Supports | First : | 1.23 | Second : | 1.04 |
| MAs | MA(5) : | 1.41 |
MA(20) : | 1.38 |
| MA(100) : | 1.37 |
MA(250) : | 5.46  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 56.9 |
D(3) : | 48.6 |
| RSI | RSI(14): 62.6 |
|||
| 52-week | High : | 11.26 | Low : | 1.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MRNS ] has closed above the upper band by 0.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 84.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 91 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.51 - 1.52 | 1.52 - 1.52 |
| Low: | 1.39 - 1.39 | 1.39 - 1.4 |
| Close: | 1.49 - 1.5 | 1.5 - 1.51 |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Thu, 12 Sep 2024
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 - Business Wire
Thu, 12 Sep 2024
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 - StockTitan
Tue, 10 Sep 2024
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference - Business Wire
Tue, 10 Sep 2024
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 3.809e+007 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 2,510 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2866e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -376 % |
| Return on Assets (ttm) | -57.8 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 3.026e+007 % |
| Gross Profit (p.s.) | 29.01 |
| Sales Per Share | 880.84 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -120 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.96 |
| Dividend | 0 |
| Forward Dividend | 2.74e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|